GSNO Therapeutics

GSNO Therapeutics’ technology has one target, the enzyme GSNOR, but many therapeutic benefits that have shown activity in numerous models of human disease. The company is concentrating on rheumatoid arthritis (RA), a debilitating chronic autoimmune disease affecting joints and other tissues. There is a business opportunity for novel drugs with novel mechanisms of action, since existing RA therapies help manage patient pain and symptoms, and a minority can slightly slow disease progression, but all carry risks for serious side effects, and efficacy wanes over time. Improved RA drug safety and efficacy would prevent painful, debilitating diseases for 1.3 million Americans and increase their life expectancy. RA is also an economic burden on the U.S. healthcare system and the economy.  

The Company has invented, synthesized, and developed the small molecule GSNORi, GTI-850, which in models of RA greatly suppresses autoimmunity, pro-inflammatory mediators, ROS/RNS, MMP, TNF- and other cytokines, and pro-inflammatory B & T cells that invade RA joints.